Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first Phase III trial of SEL-212

Trial Profile

A first Phase III trial of SEL-212

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs SEL 212 (Primary)
  • Indications Gout
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2019 According to a Selecta Biosciences media release, the company plans to initiate this trial in the fourth quarter of 2019.
    • 08 Aug 2018 According to a Selecta Biosciences media release, the company's end-of-Phase 2 meeting with the US FDA will define the design of the Phase 3 program. This study is expected to start in the fourth quarter of 2018.
    • 02 Jan 2018 According to a Selecta Biosciences media release, this trial is expected to start in the second half of 2018 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top